Evidence-graded strategy reports
Strategy Reports are how Integral BioStrategy thinks in public — not blog posts or generic summaries. Each one separates approved evidence from trial findings and emerging hypotheses, reads mechanism against outcome, and ends with decision-relevant insight.
How we grade evidence
Strategy Reports are evidence-graded, structured analyses for biotech, BD, investors, and translational teams. Not every claim carries the same weight, so we label each one by stage — and the difference between an approval, a single trial, and an early hypothesis is never blurred. For essay-style perspectives and founder viewpoints, see Insights.
GLP-1 and Incretin Therapeutics
A specific, worked example of the evidence-graded method: from a single diabetes drug to a multi-organ metabolic platform — approved indications, trial evidence, emerging frontiers, mechanism read against outcome, and the trials that defined the field.
Read the report → PublishedMetabolism as Platform Medicine
A market and evidence report on metabolic disease as a cross-organ, multi-specialty strategic category — disease burden, the evidence-architecture gap, two case studies, where capital is moving, and strategic white space. Builds on the Insight Essay, The Translational Gap in Metabolic Disease.
Read the report →MASH / NASH therapeutic landscape
The emerging treatment landscape for metabolic dysfunction-associated steatohepatitis, graded by evidence stage.
Beta-cell preservation and islet biology
What is known, contested, and unproven about preserving beta-cell function and islet health.
Obesity pharmacotherapy beyond GLP-1
Amylin, polyagonism, oral small molecules, and other mechanisms shaping the next wave of obesity therapeutics.
Metabolic disease biomarkers
Decision-relevant biomarkers and endpoints that connect preclinical mechanism to clinical readouts.
Cardiometabolic organ protection
How metabolic therapies reach the kidney, liver, heart, and vasculature — and what that means for indication strategy.
"Planned" reports are in development and not yet available. This page lists only what is published.
A strategy question to pressure-test?
For confidential biotech, spinout, investor, or strategic diligence inquiries, start with a brief scoping conversation.
Request a confidential scoping callPrefer email? [email protected]